CancerDetect
Tissue-informed personalized molecular residual disease and recurrence-monitoring assay for solid tumors.
- Developer
- IMBdx
- Intended use
- Mrd, Recurrence Detection
- Cancer scope
- Solid tumors
- Specimen
- FFPE tumor tissue, Peripheral whole blood
- Molecular modality
- DNA mutation
- Current version
- Current tissue-informed personalized CancerDetect MRD/recurrence configuration (2026-09)
- Evidence context
- 0 structured studies · 0 indexed performance results · 1 sources
Why can reported performance numbers differ? MDI keeps each result attached to its study, population, stage or stratum, test version and source rather than treating performance as a fixed property of the test.